October 14, 2025

Key IPO details (at-a-glance) About the company Canara HSBC Life Insurance Company Limited is a joint-venture life insurer backed by Canara Bank and HSBC Insurance (Asia Pacific) Holdings. It distributes life insurance products through bancassurance (partner banks), agency, and other channels across India. The company has scale in retail protection and savings products and a nationwide presence supported by its bank partners. (Reuters) Key management (From RHP and public disclosures) Major products & distribution Financial snapshot (high-level) (For full audited numbers, solvency ratio, Value of New Business (VNB) margin, persistency and channel-wise APE — read the company’s RHP / red-herring prospectus.) (canarahsbclife.com) Valuation & market view Major competitors Risks & what to watch SEO-friendly content tips (for republishing / bloggers) Suggested keywords: Canara HSBC Life IPO, Canara HSBC Life IPO date, Canara HSBC IPO price band, Canara HSBC lot size, should I apply Canara HSBC IPO.Suggested meta title: Canara HSBC Life IPO 2025 — Dates, Price Band, Lot Size, Financials & Should You Apply?Suggested meta description: Read our complete Canara HSBC Life Insurance IPO guide — opening 10 Oct 2025, price band ₹100–₹106, lot 140. Learn about the OFS structure, financials, risks and our recommendation. (The Economic Times) Conclusion & Recommendation Short answer: Apply cautiously only if you are a medium- to long-term investor comfortable with insurance-sector risks — otherwise consider skipping if you’re seeking a short-term listing gain. Why (summary): Practical approach: Where to verify official details (must-read) Quick FAQ Q: Is the company raising fresh capital through this IPO?A: No — it’s an OFS. Proceeds go to selling shareholders. (The Economic Times) Q: What is the minimum money required to apply (retail)?A: One lot (140 shares). At ₹106 upper band that equals ₹14,840. Check your broker for exact blocking. (Moneycontrol) Q: Is this a good listing-flip candidate?A: Early GMP (~₹9–₹10) suggests modest listing interest, but GMPs are unofficial and volatile. If you seek a quick flip, understand listing risk; if you are long-term, focus on business metrics. (mint)

Quick facts (at-a-glance) About Rubicon Research (short overview) Rubicon Research Limited is an Indian pharmaceutical company focused on specialty formulations and generics — supplying mostly to regulated markets. The company has reported robust revenue and profit growth in recent years, invests heavily in R&D (a higher R&D spend compared to many peers), and has been backed by private equity (General Atlantic was a major shareholder pre-IPO). The IPO values the company in the ~₹7,500–8,000 crore range at the stated price band. (The Week) (For a detailed look, read the company’s Draft Red Herring Prospectus on their investor page.) (Rubicon) Key management & ownership snapshot Major products / Business model Financial snapshot & growth (summary) Competitors / Industry peers What analysts and the market are saying (high level) Pros (Why investors may like Rubicon) Cons / Risks (what to watch) IPO application practicals (how much to keep ready) Our Recommendation — Apply or Not? Short answer: Apply with caution — consider 1 lot if you want long-term exposure; avoid large short-term bets unless you are comfortable with concentration risks and valuation. Why (summary):